帕利哌酮缓释剂治疗首发、复发精神分裂症患者的临床疗效以及对患者社会功能改善的作用

The effect of paliperidone on clinical symptoms and social function in patients with first-episode and recurrent schizophrenia

目的探讨帕利哌酮缓释剂对首发、复发精神分裂症患者的疗效及其社会功能的作用。方法选取2014年1月至2016年1月期间在我院接受治疗的20例首发精神分裂症患者(首发组)和20例复发精神分裂症患者(复发组)作为本研究对象,两组患者均采用帕利哌酮缓释剂进行治疗。分别对两组患者的治疗前、治疗2周、4周和8周后的阴性与阳性症状量表(PANSS)、治疗前后的社会功能改善(PSP总分)、临床疗效以及药物不良反应的发生率进行比较。结果治疗前,两组患者PANSS量表评分无明显差异(P>0.05),治疗2周、4周和8周后,首发组患者间的PANSS总分、阴性症状、阳性症状及一般病理量表评分较治疗前降低,差异显著(P<0.05);复发组患者的PANSS总分、阳性症状及一般病理量表评分亦比治疗前低(P<0.05),但阴性症状治疗2周时差异不明显,但在治疗4周后差异有统计学意义(P<0.05);两组患者治疗8周后的PSP总分与治疗前差异有统计学意义(P<0.05),两组间比较差异无统计学意义(P>0.05);首发组的临床显效率和不良反应总发生率与复发组无明显差异(P>0.05)。结论帕利哌酮缓释剂治疗首发、复发精神分裂症患者的阴阳性症状的疗效均较为显著,同时可以提高患者的社会功能。

Objective To investigate the effect of paliperidone on clinical symptoms and social function in patients with first-episode and recurrent schizophrenia. Methods 20 first episode schizophrenia patients （ the first group ） and the 20 recurrence schizophrenia patients （ recurrence group ） were selected, all of patients in two groups were treated with paliperidone. The positive and negative symptoms scale （ PANSS ）, social function （ PSP score ）, and incidence of adverse events between two group were compared before treatment and after 2 weeks, 4 weeks, 8 weeks treatment. Results Befi）re treatment, the scores of PANSS in two groups had no significant difference （ P〉0.05 ） . After 2 weeks, 4 weeks and 8 weeks of treatment, the scores of PANSS, positive symptoms, negative symptoms and general pathology in first group were lower than before treatment, the difference was significant （ P〈0.05 ）, And the PANSS score, positive symptoms and general pathology scores in recurrence group of patients were lower than before treatment （ P〈0.05 ） . There were no statistically significant on scores of negative symptoms between after 2 weeks of treatment and before treatment in recurrence group, but there were the difference between before treatment and after 4, 8 weeks of treatment in recurrence group. （P 〈 0.05 ） ; after 8 weeks of treatment, the score of PSP were lower than those before treatment （ P〈0.05 ）, there was no significant difference between two groups （ P〉0.05 ） . Conclusion The paliperidone have significant efficacy on positive and negative symptoms in first-episode and recurrent schizophrenic patients, and can improve the patient＇s social function to a certain extent.